Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 42, Issue 8, Pages 977-989Publisher
WILEY-BLACKWELL
DOI: 10.1111/apt.13363
Keywords
-
Funding
- Swiss National Science Foundation [33CSC0_160115/1, 32003B_135664/1, 310030120312, 320000-114009/3, 32473B_135694/1]
- MSD Merck Sharp & Dohme AG Switzerland
- Tillotts Pharma AG Switzerland
- Takeda AG Switzerland
- Otsuka AG Switzerland
- Zurich Center for Integrative Human Physiology of the University of Zurich
Ask authors/readers for more resources
Background The impact of early treatment with immunomodulators (IM) and/or TNF antagonists on bowel damage in Crohn's disease (CD) patients is unknown. Aim To assess whether 'early treatment' with IM and/or TNF antagonists, defined as treatment within a 2-year period from the date of CD diagnosis, was associated with development of lesser number of disease complications when compared to 'late treatment', which was defined as treatment initiation after >2 years from the time of CD diagnosis. Methods Data from the Swiss IBD Cohort Study were analysed. The following outcomes were assessed using Cox proportional hazard modelling: bowel strictures, perianal fistulas, internal fistulas, intestinal surgery, perianal surgery and any of the aforementioned complications. Results The 'early treatment' group of 292 CD patients was compared to the 'late treatment' group of 248 CD patients. We found that 'early treatment' with IM or TNF antagonists alone was associated with reduced risk of bowel strictures [hazard ratio (HR) 0.496, P = 0.004 for IM; HR 0.276, P = 0.018 for TNF antagonists]. Furthermore, 'early treatment' with IM was associated with reduced risk of undergoing intestinal surgery (HR 0.322, P = 0.005), and perianal surgery (HR 0.361, P = 0.042), as well as developing any complication (HR 0.567, P = 0.006). Conclusions Treatment with immunomodulators or TNF antagonists within the first 2 years of CD diagnosis was associated with reduced risk of developing bowel strictures, when compared to initiating these drugs >2 years after diagnosis. Furthermore, early immunomodulators treatment was associated with reduced risk of intestinal surgery, perianal surgery and any complication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available